Loading data...
MycoGenome Inc.
President and CEO
Hayashi Osamu
Unlocking the potential of microorganisms to create a sustainable future
Recent News & PR
Summary
Message to Participants
Detailed Information
MycoGenome Inc. provides non-GMO genome editing technology utilizing fungi, aiming for innovation in the fields of food, agriculture, medicine, environment, and energy. With our unique 'MycoEdita' technology, we are committed to contributing to the realization of a sustainable society.
Unfair Advantage & Strengths
N/A
Competitors
N/A
Company Profile
事業カテゴリ
DeepTech, Climate / Energy / Sustainability, Healthcare / Biotech
本社所在地
Chiyoda-ku, Tokyo, Japan
設立日
2024年12月26日
資本金
30百万円(見込み)
Employee Count
2
Industry Outlook & Trends for MycoGenome Inc.
Driven by aging populations and rising healthcare costs, the healthcare and biotech market where MycoGenome Inc. operates is growing globally. Telemedicine, digital health via wearables, AI-driven drug discovery, and gene therapy are advancing rapidly. The industry is shifting from treatment to prevention, increasing demand for highly personalized health solutions like those developed by MycoGenome Inc..
🔒
VPO Investor Pro Features
You are viewing a basic startup profile. Create a free account to access the dashboard. You can also upgrade to the "Investor Pro" plan to unlock full access to the following premium databases and features:
🎬
Elevator & Full Pitch Video
Watch full presentations with English/Japanese subtitles.
📊
AI Quick Report & Valuation
Get AI-driven assessment scores on market, product, and traction.
📅
Priority Challenges & Hiring
Access core corporate bottlenecks and current hiring plans.
📝
Full Transcripts
Read full pitch dialogue in both English and Japanese.
📈
Financials & Exit Strategy
Unlock IPO/M&A timelines and debt/equity plans.
👥
Advisors & Key Members
View internal team details and advisory board configurations.